The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review.

Brain Neoplasms / radiotherapy Humans Immunotherapy / adverse effects Melanoma / therapy Radiosurgery / methods Retrospective Studies
Brain metastases Immunotherapy Overall survival Stereotactic radiotherapy Toxicity

Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 27 01 2022
accepted: 06 05 2022
pubmed: 24 5 2022
medline: 27 7 2022
entrez: 23 5 2022
Statut: ppublish

Résumé

Aim of this study was to systematically review the literature to assess efficacy and safety of stereotactic radiotherapy (SRT) in combination with immunotherapy for the treatment of melanoma brain metastases (MBM). The literature was searched using PubMed, Scopus, and Embase. Studies comparing SRT plus immunotherapy versus SRT or immunotherapy alone were deemed eligible for inclusion. Two studies showed improved overall survival after SRT plus immunotherapy in melanoma cancer patients with brain metastases. Three studies reported data on LC and DFS showing as SRT plus immunotherapy did not improve local control and DFS rates. G3-G4 toxicity was reported in only one study (20% in the SRT plus immunotherapy group versus 23% in the immunotherapy group). Despite SRT plus concurrent immunotherapy seems associated with possible survival advantage and low ≥ G3 late toxicity rates, the quality of evidence is very low. Therefore, in patients with brain metastases from melanoma, SRT plus immunotherapy should be evaluated on an individual basis after discussion by a multidisciplinary team.

Identifiants

DOI: 10.1007/s11547-022-01503-7 PMID: 35606609 PMC: PMC9308608
pubmed: 35606609
doi: 10.1007/s11547-022-01503-7
pii: 10.1007/s11547-022-01503-7
pmc: PMC9308608
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

773-783

Informations de copyright

© 2022. The Author(s).

Références

Katalin L, Serge MC, Udo SG, Benjamin F (2018) Editorial: radiation and the immune system: current knowledge and future perspectives. Front Immunol 8:1933. https://doi.org/10.3389/fimmu.2017.01933
doi: 10.3389/fimmu.2017.01933
Spagnolo F, Picasso V, Lambertini M, Ottaviano V, Dozin B, Queirolo P (2016) Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review. Cancer Treat Rev 45:38–45. https://doi.org/10.1016/j.ctrv.2016.03.003
doi: 10.1016/j.ctrv.2016.03.003 pubmed: 26975020
Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687–1696. https://doi.org/10.1002/cncr.25634
doi: 10.1002/cncr.25634 pubmed: 20960525
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459–465. https://doi.org/10.1016/S1470-2045(12)70090-6
doi: 10.1016/S1470-2045(12)70090-6 pubmed: 22456429
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol S1470e2045:30053–30055. https://doi.org/10.1016/S1470-2045(16)30053-5
doi: 10.1016/S1470-2045(16)30053-5
Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19:672–681. https://doi.org/10.1016/S1470-2045(18)30139-6
doi: 10.1016/S1470-2045(18)30139-6 pubmed: 29602646
Tawbi H, Forsyth P, Algazi A, Hamid O, Hodi S, Moschos SJ (2018) Efficacy and safety of Nivolumab plus ipilimumab in patients with melanoma metastatic to the brain: results of the phase II study checkmate 204. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 379:722–730. https://doi.org/10.1056/NEJMoa1805453
doi: 10.1056/NEJMoa1805453 pubmed: 30134131 pmcid: 8011001
Bernstein MB, Krishnan S, Hodge JW, Chang JY (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13:516–524. https://doi.org/10.1038/nrclinonc.2016.30
doi: 10.1038/nrclinonc.2016.30 pubmed: 26951040 pmcid: 6053911
Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS (2018) Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 15:477–494. https://doi.org/10.1038/s41571-018-0046-7
doi: 10.1038/s41571-018-0046-7 pubmed: 29872177
Kroeze SG, Fritz C, Hoyer M et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37. https://doi.org/10.1016/j.ctrv.2016.11.013
doi: 10.1016/j.ctrv.2016.11.013 pubmed: 28056412
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:65–94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136
doi: 10.7326/0003-4819-151-4-200908180-00136
Trommer-Nestler M, Marnitz S, Kocher M et al (2018) Robotic Stereotactic radiotherapy in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. Int J Mol Sci 19:2653. https://doi.org/10.3390/ijms19092653
doi: 10.3390/ijms19092653 pmcid: 6164579
Tetu P, Allayous C, Oriano B et al (2019) Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. Eur J Cancer 112:38–46. https://doi.org/10.1016/j.ejca.2019.02.009
doi: 10.1016/j.ejca.2019.02.009 pubmed: 30909072
Mathew M, Tam M, Ott PA et al (2013) Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiotherapy. Melanoma Res 23:191–195. https://doi.org/10.1097/CMR.0b013e32835f3d90
doi: 10.1097/CMR.0b013e32835f3d90 pubmed: 23462208
Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD (2013) Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:899–906. https://doi.org/10.1002/cam4.140
doi: 10.1002/cam4.140 pubmed: 24403263 pmcid: 3892394
Kiess AP, Wolchok JD, Barker CA et al (2015) Stereotactic radiotherapy for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. https://doi.org/10.1016/j.ijrobp.2015.01.004
doi: 10.1016/j.ijrobp.2015.01.004 pubmed: 25754629 pmcid: 4955924
Schoenfeld JD, Mahadevan A, Floyd SR et al (2015) Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 3:50. https://doi.org/10.1186/s40425-015-0095-8
doi: 10.1186/s40425-015-0095-8 pubmed: 26672895 pmcid: 4678639
Greto D, Scoccianti S, Compagnucci A et al (2016) Gamma Knife Radiosurgery in the management of single and multiple brain metastases. Clin Neurol Neurosurg 141:43–47. https://doi.org/10.1016/j.clineuro.2015.12.009
doi: 10.1016/j.clineuro.2015.12.009 pubmed: 26731463
Antonia SJ, Villegas A, Daniel D et al (2017) PACIFIC investigators. durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937
doi: 10.1056/NEJMoa1709937 pubmed: 28885881
Cao Y, Tsien CI, Shen Z et al (2005) Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23:4127–4136
doi: 10.1200/JCO.2005.07.144
Desideri I, Francolini G, Scotti V et al (2019) Beneft of ablative versus palliative-only radiotherapy in combination with nivolumab in patients afected by metastatic kidney and lung cancer. Clin Transl Oncol 21:933–938. https://doi.org/10.1007/s12094-018-02005-7
doi: 10.1007/s12094-018-02005-7 pubmed: 30565084
Lehrer EJ, Peterson J, Brown PD et al (2019) Treatment of brain metastases with stereotactic radiotherapy and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiother Oncol 130:104–112. https://doi.org/10.1016/j.radonc.2018.08.025
doi: 10.1016/j.radonc.2018.08.025 pubmed: 30241791
Franceschini D, Franzese C, Navarria P et al (2016) Radiotherapy and immunotherapy: can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat Rev 50:1–8. https://doi.org/10.1016/j.ctrv.2016.08.003
doi: 10.1016/j.ctrv.2016.08.003 pubmed: 27566962

Auteurs

Valentina Lancellotta (V)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
ORCID: 0000-0003-3507-7051

Laura Del Regno (L)

Institute of Dermatology, Catholic University, Rome, Italy.

Alessandro Di Stefani (A)

Institute of Dermatology, Catholic University, Rome, Italy.
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Bruno Fionda (B)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Fabio Marazzi (F)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Ernesto Rossi (E)

Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Mario Balducci (M)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Riccardo Pampena (R)

Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
Radiotherapy Center, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Alessio Giuseppe Morganti (AG)

Radiotherapy Center, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
DIMES, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Monica Mangoni (M)

Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

Celeste Lebbe (C)

Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France.

Claus Garbe (C)

Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris, France.

Caterina Longo (C)

Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
Radiotherapy Center, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Giovanni Schinzari (G)

Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Luca Tagliaferri (L)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. luca.tagliaferri@policlinicogemelli.it.
ORCID: 0000-0003-2308-0982

Ketty Peris (K)

Institute of Dermatology, Catholic University, Rome, Italy.
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › The role of stereotactic radiotherapy in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The role of stereotactic radiotherapy in...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › The role of stereotactic radiotherapy in...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › The role of stereotactic radiotherapy in...
questionsmedicales.fr › Techniques d'investigation › Techniques stéréotaxiques › Radiochirurgie › The role of stereotactic radiotherapy in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › The role of stereotactic radiotherapy in...